Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.12289 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular and functional characterization of reversible-sunitinib-tolerance state in human renal cell carcinoma.
J Cell Mol Med
May 2024
Department of Urology and Pediatric Urology, Saarland University, Homburg, Germany.
Therapy failure with the tyrosine kinase inhibitor (TKI) sunitinib remains a great challenge in metastatic renal cell carcinoma (mRCC). Growing evidence indicates that the tumour subpopulation can enter a transient, non-mutagenic drug-tolerant state to endure the treatment underlying the minimal residual disease and tumour relapse. Drug tolerance to sunitinib remains largely unexplored in RCC.
View Article and Find Full Text PDFRole for ubiquitin-specific protease 7 (USP7) in the treatment and the immune response to hepatocellular carcinoma: potential mechanisms.
Transl Cancer Res
November 2023
Department of Infectious Diseases, Affiliated Hospital of Nantong University, Nantong, China.
Background: Ubiquitin-specific protease 7 (USP7) is a deubiquitinating enzyme that can affect or regulate a variety of cellular activities. The purpose of this study was to investigate therapeutic and immunologic effects of USP7 in hepatocellular carcinoma (HCC), and as well to evaluate potential mechanisms of action.
Methods: USP7-related gene expression and clinical data were obtained from The Cancer Genome Atlas (TCGA) dataset, International Cancer Genome Consortium (ICGC) dataset, and Gene Expression Omnibus (GEO) dataset.
Clinical uses and safety concerns of tyrosine kinase inhibitors with a focus on novel drugs: A narrative review.
J Oncol Pharm Pract
May 2023
Clinical Pharmacy, Pharmaceutical Sciences Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.
To review the safety issues surrounding tyrosine kinase inhibitors (TKIs), specifically, hematological adverse effects, cardiovascular issues, renal adverse effects and nephrotoxicity, endocrine system adverse effects, concerns related to the reproductive system, dermatological and gastrointestinal adverse effects. A literature search was performed through Web of Science, PubMed, Google Scholar, Scopus, and the Food and Drug Administration. Several safety issues have been raised following the use of TKIs.
View Article and Find Full Text PDFDisparity in public funding of systemic therapy for metastatic renal cell carcinoma in Canada.
Can Urol Assoc J
November 2022
Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
Introduction: There have been significant advances in systemic therapies for metastatic renal cell carcinoma (mRCC). There are currently 11 drugs approved by Health Canada: sunitinib, sorafenib, pazopanib, axitinib, everolimus, temsirolimus, nivolumab, ipilimumab, cabozantinib, lenvatinib, and pembrolizumab. These novel medications have dramatically altered the prognosis and patient experience.
View Article and Find Full Text PDFPembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence.
Curr Probl Cancer
August 2022
Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
The recent introduction of immunotherapy in the first line setting of advanced renal cell carcinoma (aRCC) has dramatically improved patients' prognosis. The aim of the current meta-analysis was to provide level 1a evidence supporting the use of pembrolizumab plus tyrosine kinase inhibitors (TKI) as first-line treatment for advanced RCC. All published randomized prospective trials including patients with advanced RCC treated with pembrolizumab in combination with TKIs vs Sunitinib were included in this meta-analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!